CO6270226A2 - Nuevos compuestos espirociclicos como antagonistas de cgrp - Google Patents

Nuevos compuestos espirociclicos como antagonistas de cgrp

Info

Publication number
CO6270226A2
CO6270226A2 CO10044754A CO10044754A CO6270226A2 CO 6270226 A2 CO6270226 A2 CO 6270226A2 CO 10044754 A CO10044754 A CO 10044754A CO 10044754 A CO10044754 A CO 10044754A CO 6270226 A2 CO6270226 A2 CO 6270226A2
Authority
CO
Colombia
Prior art keywords
compounds
new
spirociclical
cgrp antagonists
salts
Prior art date
Application number
CO10044754A
Other languages
English (en)
Inventor
Dirk Gottschling
Georg Dahmann
Dirk Stenkamp
Gerhard Schaenzle
Klaus Rudolf
Stephan Georg Mueller
Annekatrin Heimann
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6270226A2 publication Critical patent/CO6270226A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Son objeto de la presente invencion nuevos antagonistas de CGRP de la formula general (I)en la que U, V, X, Y, R1, R2 y R3 estan definidos como se menciona en lo que sigue, sus tautomeros, sus isomeros, sus diastereoisomeros, sus enantiomeros, sus hidratos, sus mezclas y sus sales, asi como los hidratos de las sales, en especial sus sales fisiologicamente compatibles con acidos o bases inorganicos u organicos, medicamentos que contienen a estos compuestos, su uso y procedimientos para su preparacion.
CO10044754A 2007-10-18 2010-04-16 Nuevos compuestos espirociclicos como antagonistas de cgrp CO6270226A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118811 2007-10-18

Publications (1)

Publication Number Publication Date
CO6270226A2 true CO6270226A2 (es) 2011-04-20

Family

ID=39047647

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10044754A CO6270226A2 (es) 2007-10-18 2010-04-16 Nuevos compuestos espirociclicos como antagonistas de cgrp

Country Status (17)

Country Link
US (1) US8450327B2 (es)
EP (2) EP2205599B1 (es)
JP (1) JP5366960B2 (es)
KR (1) KR20100091972A (es)
CN (1) CN101827845A (es)
AU (1) AU2008313733A1 (es)
BR (1) BRPI0817835A2 (es)
CA (1) CA2702503A1 (es)
CO (1) CO6270226A2 (es)
EA (1) EA201000612A1 (es)
EC (1) ECSP10010105A (es)
IL (1) IL204928A0 (es)
MA (1) MA31782B1 (es)
MX (1) MX2010003849A (es)
NZ (1) NZ585347A (es)
TN (1) TN2010000173A1 (es)
WO (1) WO2009050234A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817835A2 (pt) 2007-10-18 2015-03-31 Boehringer Ingelheim Int Antagonistas cgrp
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2225223B1 (de) * 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
JP5603409B2 (ja) 2010-03-12 2014-10-08 日本曹達株式会社 ｔ−ブトキシカルボニルアミン化合物の製造方法
AU2015214502B2 (en) 2014-02-05 2019-06-06 Merck Sharp & Dohme Llc Tablet formulation for CGRP-active compounds
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL343406A1 (en) 1998-04-10 2001-08-13 Searle & Co Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1322628A2 (en) 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
KR20120004541A (ko) 2002-06-05 2012-01-12 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2579221A1 (en) 2004-09-08 2006-03-16 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
ATE537153T1 (de) * 2004-09-09 2011-12-15 Merck Sharp & Dohme Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU2006251624A1 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
RU2008103218A (ru) 2005-06-29 2009-08-10 Палау Фарма С.А. (Es) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ p38-КИНАЗЫ
DE102005050892A1 (de) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP2024358B1 (en) 2006-05-09 2014-11-05 Merck Sharp & Dohme Corp. Substituted spirocyclic cgrp receptor antagonists
WO2008070014A2 (en) 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
WO2009034029A2 (de) 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
EP2065381A1 (de) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
BRPI0817835A2 (pt) 2007-10-18 2015-03-31 Boehringer Ingelheim Int Antagonistas cgrp
US20120149698A1 (en) * 2007-11-22 2012-06-14 Boehringer Ingelheim International Gmbh Nouvel compounds
EP2225223B1 (de) * 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen

Also Published As

Publication number Publication date
BRPI0817835A2 (pt) 2015-03-31
AU2008313733A1 (en) 2009-04-23
EP2205599B1 (de) 2012-06-06
MA31782B1 (fr) 2010-10-01
US20110172218A1 (en) 2011-07-14
JP2011500637A (ja) 2011-01-06
CN101827845A (zh) 2010-09-08
NZ585347A (en) 2011-09-30
EP2386558A1 (de) 2011-11-16
MX2010003849A (es) 2010-04-27
EP2205599A1 (de) 2010-07-14
JP5366960B2 (ja) 2013-12-11
WO2009050234A1 (de) 2009-04-23
EP2386558B1 (de) 2014-10-01
KR20100091972A (ko) 2010-08-19
ECSP10010105A (es) 2010-06-29
US8450327B2 (en) 2013-05-28
IL204928A0 (en) 2010-11-30
EA201000612A1 (ru) 2010-10-29
CA2702503A1 (en) 2009-04-23
TN2010000173A1 (fr) 2011-11-11

Similar Documents

Publication Publication Date Title
UY29437A1 (es) Nuevos antagonistas de cgrp
CO6270226A2 (es) Nuevos compuestos espirociclicos como antagonistas de cgrp
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
UY28040A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos.
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
UY29749A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
ECSP10010722A (es) Compuestos orgánicos
DOP2011000176A (es) Compuestos organicos
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
ECSP088638A (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
CR9786A (es) Compuestos de bencimidazol-tiofeno
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
UY30979A1 (es) Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos
CO6331335A2 (es) Nuevos compuestos antagonistas de los receptores b1 de bradiquinina
ECSP078058A (es) Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos
AR058127A1 (es) Derivados de piperidina antagonistas de cgrp, procedimientos para su preparacion asi como su uso como medicamentos
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos

Legal Events

Date Code Title Description
FC Application refused